Hillevax Inc Quick Ratio (HLVX) starting from the second quarter 2025 to second quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Hillevax Inc   (NASDAQ: HLVX)

Hillevax Inc 's Quick Ratio

HLVX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Hillevax Inc 's Cash & cash equivalent grew by 0.01 % in the Q2 2025 sequentially, while Current Liabilities decreased, this led to improvement in Hillevax Inc 's Quick Ratio to 25.96, above Hillevax Inc average Quick Ratio.

Within Biotechnology & Pharmaceuticals industry 3 other companies have achieved higher Quick Ratio than Hillevax Inc in second quarter 2025. While Quick Ratio total ranking has improved so far during the Q2 2025 to 82, from total ranking in the first quarter 2025 at 95.

Explain Quick Ratio?
How much Cash & cash equivalents HLVX´s has?
What are HLVX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

HLVX Quick Ratio (Jun 30 2025)
Q2		 (Mar 31 2025)
Q1		 (Dec 31 2024)
Q4		 (Sep 30 2024)
Q3		 (Jun 30 2024)
Q2
Y / Y Current Liabilities Change -87.5 % -74.58 % -45.56 % -27.02 % 168.1 %
Y / Y Cash & cash equivalent Change -34.89 % -41.51 % -43.51 % -41.64 % 0.41 %
Quick Ratio MRQ 25.96 24.38 10.42 13.68 4.98
HLVX's Total Ranking # 82 # 95 # 268 # 195 # 570
Seq. Current Liabilities Change -6.08 % -60.22 % 18.93 % -71.86 % 90.94 %
Seq. Cash & cash equivalent Change 0.01 % -6.94 % -9.44 % -22.74 % -10.16 %



Quick Ratio second quarter 2025 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 4
Healthcare Sector # 21
Overall Market # 82


Quick Ratio Statistics
High Average Low
33.83 16.08 0.39
(Sep 30 2022)   (Mar 31 2022)




Financial Statements
Hillevax Inc 's Current Liabilities $ 6 Millions Visit HLVX's Balance sheet
Hillevax Inc 's Cash & cash equivalent $ 160 Millions Visit HLVX's Balance sheet
Source of HLVX's Sales Visit HLVX's Sales by Geography


Cumulative Hillevax Inc 's Quick Ratio

HLVX's Quick Ratio for the trailling 12 Months

HLVX Quick Ratio

 (Jun 30 2025)
12 Months		 (Mar 31 2025)
12 Months		 (Dec 31 2024)
12 Months		 (Sep 30 2024)
12 Months		 (Jun 30 2024)
12 Months
Y / Y Current Liabilities TTM Growth -65.36 % -7.79 % 21.21 % 70.9 % 109.31 %
Y / Y Cash & cash equivalent TTM Growth -40.66 % -33.14 % -22.43 % -8.83 % 6.47 %
Quick Ratio TTM 15.82 8.9 8.35 8.49 9.23
Total Ranking TTM # 3230 # 2900 # 2951 # 93 # 2905
Seq. Current Liabilities TTM Growth -50.02 % -18.25 % -11.57 % -4.13 % 33.05 %
Seq. Cash & cash equivalent TTM Growth -11.17 % -12.89 % -13.07 % -11.79 % 0.09 %

Quick ratio ranking by company, industry and sector >> Back to HLVX Financial Strength Comparisons >> Go to Compare HLVX Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Hillevax Inc 's average Cash & cash equivalent, this led to increase in in Hillevax Inc 's Quick Ratio to 15.82, above HLVX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 157 other companies have achieved higher Quick Ratio than Hillevax Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2025 from 2900 to 3230.

Explain Quick Ratio?
How much Cash & cash equivalents HLVX´s has?
What are HLVX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 158
Healthcare Sector # 916
Within the Market # 3230


trailing twelve months Quick Ratio Statistics
High Average Low
21.45 12.29 3.14
(Mar 31 2023)   (Dec 31 2022)




Companies with similar Quick Ratio in the quarter ending Jun 30 2025, within Biotechnology & Pharmaceuticals Industry Quick RatioJun 30 2025 MRQ Cash & cash equivalentJun 30 2025 MRQ Current Liabilities
Viskase Holdings inc   55.16 $ 44.294  Millions$ 0.803  Millions
Tarsus Pharmaceuticals Inc   32.82 $ 381.143  Millions$ 11.612  Millions
Voyager Therapeutics Inc   31.36 $ 433.653  Millions$ 13.829  Millions
Hillevax Inc   25.96 $ 159.547  Millions$ 6.147  Millions
Tectonic Therapeutic Inc   25.30 $ 287.381  Millions$ 11.361  Millions
Tourmaline Bio Inc   24.04 $ 239.234  Millions$ 9.950  Millions
Cg Oncology Inc   21.76 $ 661.052  Millions$ 30.381  Millions
Artiva Biotherapeutics Inc   20.19 $ 142.400  Millions$ 7.053  Millions
Kymera Therapeutics Inc   19.64 $ 665.445  Millions$ 33.874  Millions
Crispr Therapeutics Ag  16.49 $ 1,721.237  Millions$ 104.362  Millions
Apogee Therapeutics Inc   16.02 $ 505.420  Millions$ 31.551  Millions
Cidara Therapeutics Inc   15.80 $ 510.575  Millions$ 32.318  Millions
Qiagen N v   15.12 $ 1,098.918  Millions$ 72.656  Millions
Inhibikase Therapeutics Inc   14.89 $ 87.666  Millions$ 5.887  Millions
Maze Therapeutics Inc   13.29 $ 264.541  Millions$ 19.900  Millions
Genenta Science S p a   13.29 $ 31.527  Millions$ 2.372  Millions
Imagenebio Inc   13.06 $ 95.642  Millions$ 7.324  Millions
In8bio Inc   13.04 $ 13.226  Millions$ 1.014  Millions
Pharmacyte Biotech Inc   12.67 $ 13.440  Millions$ 1.061  Millions
Protara Therapeutics Inc  12.52 $ 122.216  Millions$ 9.761  Millions
Taysha Gene Therapies Inc   12.34 $ 312.761  Millions$ 25.349  Millions
Cargo Therapeutics Inc   12.08 $ 252.567  Millions$ 20.908  Millions
Aura Biosciences Inc   11.94 $ 177.311  Millions$ 14.852  Millions
Kalaris Therapeutics Inc   11.56 $ 88.426  Millions$ 7.651  Millions
Entera Bio Ltd   11.28 $ 10.858  Millions$ 0.963  Millions
Prokidney Corp   10.77 $ 294.728  Millions$ 27.359  Millions
Engene Therapeutics Inc   10.68 $ 201.913  Millions$ 18.913  Millions
Titan Pharmaceuticals Inc   10.66 $ 2.803  Millions$ 0.263  Millions
Century Therapeutics inc   10.43 $ 155.843  Millions$ 14.948  Millions
Acumen Pharmaceuticals Inc   10.42 $ 143.369  Millions$ 13.753  Millions

Date modified: 2026-08-29T17:47:08+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.